Rising Health Care Spending Driving the European Erythropoietin Market

Digg This
Reddit This
Stumble Now!
Buzz This
Vote on DZone
Share on Facebook
Bookmark this on Delicious
Kick It on DotNetKicks.com
Shout it
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)
Contact Us
Author
G-199, Sector 63
Noida
Uttar Pradesh 201301 
India
Phone:1204224700
Fax:1204224700
press@rncos.com

Health expenditures continue to grow rapidly in the European market. According to the Organization for Economic Development and Cooperation (OECD), average healthcare expenditures in OECD countries, such as the France and Germany amongst others, will range from 7.2% to 8.7% of GDP by 2060. This rise in healthcare expenditure is especially being observed in developed nations, such as Spain. In Spain, it will increase from US$ 2,289 (€2,100) per capita in 2015 to US$ 2,447 (€2,245) per capita in 2017.

The rising healthcare expenditure is compelling governments of European countries to search for treatment options for diseases, such as anemia caused by kidney disease, cancer or other reasons, that will help them to recover quickly at lower cost.

According to our report, “European Erythropoietin Market Outlook 2022”, a quicker recovery from anemia with the help of erythropoietin drugs will help people in reducing their hospital bills. Therefore, rising healthcare spending is likely to drive the growth of European erythropoietin industry. The use of EPO is believed to increase oxygen absorption, reduce fatigue and improve endurance by increasing the rate of red cell production. It is also believed that EPO increases the metabolism and the healing process of muscles because the extra red cells carry more oxygen and nutrients.

Many factors influence innovation in medical care. Consumer demand for better health is a prime factor. People and the nation become wealthier; they provide a fertile market for new medical innovations. Health insurance systems that provide payment for new innovations also encourage medical advances. Medical treatments can be very expensive, and their cost would be beyond the reach of many people unless their risk of needing health care could be pooled though insurance (either public or private). The presence of health insurance provides some assurance to researchers and medical suppliers that patients will have the resources to pay for new medical products, thus encouraging research and development.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM863.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

ABOUT RNCOS

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.

Comments are closed.